drugset / Trial / NCT06715683

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683

Phase 1 Completed 48 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.

Timeline

Start
2024-12-12
Primary completion
2025-03-16
Completion
2025-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule

Indications

No indication recorded.